MedTrace Logo

Apixaban in Thrombocytopenia

NCT06886516 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-15

No results posted yet for this study

Summary

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes.

The name of the study drug involved in this study is:

-Apixiban (a type of anticoagulant)

Conditions

  • Deep Vein Thrombosis
  • Pulmonary Embolism and Thrombosis
  • Thrombocytopenia
  • Recurrent Venous Thromboembolism

Interventions

DRUG

Apixaban

A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.

Sponsors & Collaborators

  • Rushad Patell

    lead OTHER

Principal Investigators

  • Rushad Patell, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2027-07-01
Completion
2029-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06886516 on ClinicalTrials.gov